Activation of STING due to cellular damage and the release of pro-inflammatory cytokines has been observed in metabolic disorders, including obesity, insulin resistance, type II diabetes, nonalcoholic steatohepatitis (NASH), and various dyslipidemias [5, 6, 8, 10, 13]. This evidence concerns the gene STING1 and Other metabolic disease.